Home/ Stocks/ MLTX

MoonLake Immunotherapeutics Class A Ordinary Shares

MLTX XNAS

$18.26 +0.23 (+1.28%) ▲ 15-min delayed

Open

$18.47

High

$18.63

Low

$17.92

Volume

902.1K

Market Cap

$1.53B

About MoonLake Immunotherapeutics Class A Ordinary Shares

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 130 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-69,707,000	$-0.98
FY 2025	$0	$-230,321,000	$-3.53
Q3 2025	$0	$-70,694,000	$-1.10
Q2 2025	$0	$-56,051,000	$-0.87

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for MLTX yet. Check out our latest market news or earnings calendar.

Get MLTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on MoonLake Immunotherapeutics Class A Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.